The purpose of this Position Statement is to provide guidance on the use of fine needle aspiration (FNA) and core biopsy for the assessment of abnormalities identified through population screening for breast cancer. The Position Statement will establish national BreastScreen Australia policy on breast biopsy and support best practice care in the BreastScreen Australia program.
Cancer Australia, the Government's national cancer control agency, aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer, by leading and coordinating national, evidence-based interventions across the continuum of care.
Please note that this information was updated in August 2021 with the final results of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The purpose of this Position Statement is to provide information and guidance in relation to routine screening of women who are at population risk of ovarian cancer, and surveillance of women who are at high or potentially high risk of developing ovarian cancer.
The purpose of this Position Statement is to provide information and recommendations on genetic testing for women diagnosed with invasive epithelial ovarian cancer, based on available evidence and on consensus. The scope of this Position Statement encompasses genetic testing for heritable, or germline, gene mutations, with a focus on genetic testing of BRCA1 and BRCA2. The intended audiences are health professionals, medical colleges, consumers, media and policy makers.
It is estimated that at least one third of all cancer cases are preventable, and that potentially more than half of all cancers could be avoided through a combination of healthy lifestyle and regular screening. Prevention offers the most cost-effective long-term strategy for the control of cancer across the population. This positon statement includes recommendations for adults to reduce their risk of cancer and stay healthy.
This position statement outlines the evidence for mammographic screening and estimates of overdiagnosis. “Overdiagnosis” from breast screening does not refer to error or misdiagnosis, but rather refers to breast cancer diagnosed by screening that would not otherwise have been diagnosed during a woman’s lifetime.
This position statement outlines the evidence for mammographic screening and estimates of overdiagnosis. “Overdiagnosis” from breast screening does not refer to error or misdiagnosis, but rather refers to breast cancer diagnosed by screening that would not otherwise have been diagnosed during a woman’s lifetime.
Familial clusters of ovarian cancer have been recognised for many years and family history has been identified as a risk factor in epidemiological studies that have investigated its role.
This position statement applies to the early detection of breast cancer in asymptomatic women (women without breast changes). The statement does not apply to diagnostic tests used to assess individual women presenting with breast changes.
Cancer Australia does not recommend the use of thermography for the early detection of breast cancer.
Although there is some looseness in usage of the terms, complementary therapies refer to those therapies that do not replace or preclude conventional medical therapies, whereas alternative therapies are treatment options outside the orthodox range, that may be used in place of conventional treatments.
This position statement applies only to Hormone Replacement Therapy (HRT) and breast cancer risk in women – it does not address other risks or benefits to women from HRT usage.
National Health and Medical Research Council (NHMRC) has released a position statement to provide information about the assessment and management of cancer clusters. The statement is intended to support guidelines issued by State and Territory Health Departments and Cancer Councils.
Additional statements that address significant clinical issues, emerging issues in cancer control and issues of ongoing interest using the best available evidence.
